养心定悸胶囊联合瑞舒伐他汀治疗急性前壁STEMI合并恶性室性心律失常临床研究OA
Clinical effect analysis of Yangxin Dingji Capsules Combined with Rosuvastatin in Treatment of Patients With Acute Anterior STEMI Complicated with Malignant Ventricular Arrhythmia
目的 探究养心定悸胶囊联合瑞舒伐他汀治疗急性前壁 ST 段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)合并恶性室性心律失常患者的临床效果.方法 选取2023 年1 月—2025 年1 月平煤神马医疗集团总医院收治的 88 例急性前壁 STEMI 合并恶性室性心律失常的患者为研究对象,依据随机数字表法将患者分为对照组和治疗组,每组 44 例.两组均给予对症西药治疗,对照组给予瑞舒伐他汀治疗,治疗组给予养心定悸胶囊+瑞舒伐他汀治疗.对比两组疗效、主要不良心血管事件(major adverse cardiovascular events,MACE)、血清肌酸激酶同工酶(creatine kinase isoenzyme,CK-MB)、高峰射血率(peak ejection rate,PER)、血浆 N 末端脑利尿钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)、左心室收缩末期内径(left ventricular end-systolic diame-ter,LVESD)、血清心肌肌钙蛋白Ⅰ(cardiac troponin I,cTnⅠ)、血清细胞间黏附分子(intercellular adhesion molecule,ICAM-1)、左心室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、血清血管性血友病因子(von Wille-brand factor,vWF)、血清内皮素-1(endothelin-1,EF-1)、左心室射血分数(left ventricular ejection fraction,LVEF)、血清一氧化氮(nitric oxide,NO)及不良反应.结果 治疗组总有效率为 95.45%,显著高于对照组的 75.00%(P<0.05);治疗后治疗组 PER、血浆 NT-proBNP 及血清 cTnⅠ、ICAM-1、vWF、EF-1、CK-MB 较对照组低,LVEF、血清 NO 较对照组高(P<0.05);治疗后两组 LVEDD、LVESD 均高于治疗前,但治疗后组间对比,差异无统计学意义(P>0.05);两组MACE 及不良反应发生率对比,差异无统计学意义(P>0.05).结论 养心定悸胶囊联合瑞舒伐他汀治疗急性前壁STEMI 合并恶性室性心律失常患者的效果可靠,能有效改善血管内皮功能,缓解心肌损伤,改善心功能.
Objective To explore the clinical effect of Yangxin Dingji capsules combined with rosuvastatin in treatment of acute anterior ST-segment elevation myocardial infarction(STEMI)complicated with malignant ventricular arrhythmia.Methods A total of 88 patients with acute anterior wall STEMI complicated with malignant ventricular arrhythmia admitted to General Hospital of Pingmei Shenma Group from January 2023 to January 2025 were selected as the research objects.According to the random number table method,the patients were divided into two groups,the control group and the treatment group had 44 cases in each group.Both groups were treated with symptomatic western medicine,the control group was treated with rosuvastatin,and the treatment group was treated with Yangxin Dingji capsule+rosuvastatin.The efficacy,major adverse cardiovascular events(MACE),serum creatine kinase isoenzyme(CK-MB),peak ejection rate(PER),plasma N-terminal pro-brain natriuretic peptide(NT-proBNP),left ventricular end-systolic diameter(LVESD),serum cardiac troponin Ⅰ(cTnⅠ),serum intercellular adhesion molecule(ICAM-1),left ventricular end diastolic diameter(LVEDD),serum von Willebrand factor(vWF),serum endothelin-1(EF-1),left ventricular ejection fraction(LVEF),serum nitric oxide(NO)and adverse reactions were compared between the two groups.Results The total effective rate of the treatment group was 95.45%,which was significantly higher than 75.00%of the control group(P<0.05).After treatment,PER,plasma NT-proBNP and serum cTnI,ICAM-1,vWF,EF-1 and CK-MB in the treatment group were lower than those in the control group,LVEF and serum NO were higher than those in the control group(P<0.05).After treatment,LVEDD and LVESD in the two groups were higher than those before treatment,but there was no significant difference between the two groups after treatment(P>0.05).There was no significant difference in the incidence of MACE and adverse reactions between the two groups(P>0.05).Conclusion Yangxin Dingji Capsule combined with rosuvastatin is effective in the treatment of patients with acute anterior STEMI complicated with malignant ventricular arrhythmia.It can effectively improve vascular endothelial function,relieve myocardial injury and improve cardiac function.
王印锋;常亚丽;兰红斌;弯战奎;孙建利
平煤神马医疗集团总医院药品调剂科,河南 平顶山 467000平煤神马医疗集团总医院药品调剂科,河南 平顶山 467000平煤神马医疗集团总医院药品调剂科,河南 平顶山 467000平煤神马医疗集团总医院药品调剂科,河南 平顶山 467000平煤神马医疗集团总医院药品调剂科,河南 平顶山 467000
医药卫生
ST段抬高型心肌梗死养心定悸胶囊瑞舒伐他汀心功能血管内皮功能
ST-segment elevation myocardial infarctionYangxin Dingji capsulesrosuvastatincardiac functionvascular endothelial function
《现代中医药》 2026 (5)
139-145,7
评论